Eagerly Awaited Expanded Xtandi Label Should Accelerate Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Medivation had already expanded its enzalutamide sales force to complement partner Astellas’ team ahead of getting a new indication for the earlier, pre-chemotherapy prostate cancer setting. The expanded label now paves the way for reps to drop in on more urologists.
You may also be interested in...
Medivation/Astellas Will Be Ready For Xtandi To Enter Pre-Chemo Prostate Cancer Setting
The oncology drug has been submitted for approval in the larger chemotherapy-naïve patient population and Medivation intends to increase its sales force to support the launch.
PREVAIL Impresses, But Prostate Docs Wary Of Declaring Victory For Xtandi Over Zytiga
Bullish analysts predicted Xtandi easily wins over first-to-market Zytiga in pre-chemo prostate cancer, based on PREVAIL findings. But in the formal presentation at the ASCO GU meeting, clinicians were more reluctant to compare the two drugs and took a more nuanced interpretation of the data, given the important differences in study designs.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.